Catyalyst Pharma (CPRX) Receives FDA Orphan Status for Treatment of Myasthenia Gravis

September 2, 2016 7:33 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Catyalyst Pharma (NASDAQ: CPRX) on August 31st received FDA orphan drug designation for its treatment of myasthenia gravis. The generic name is amifampridine phosphate.

Generic Name: amifampridine phosphate
Trade Name: N/A
Date Designated: 08/31/2016
Orphan Designation: Treatment of myasthenia gravis
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Suite 1250
Coral Gables, Florida 33134

The sponsor address listed is the last reported by the sponsor to OOPD.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment